Febuksostat – skuteczna i bezpieczna alternatywa leczenia dny moczanowej. Punkty widzenia kardiologa, reumatologa i nefrologa Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2023
Słowa kluczowe:
hiperurykemia, dna moczanowa, kwas moczowy, bezpieczeństwo sercowo-naczyniowe, inhibitor oksydazy ksantynowej, przewlekła choroba nerek
##plugins.themes.bootstrap3.article.main##
Abstrakt
Febuksostat to silny inhibitor oksydazy ksantynowej stosowany w leczeniu przewlekłej hiperurykemii z odkładaniem się złogów moczanowych. Stanowi bardzo ważną alternatywę ze względu na bezpieczeństwo stosowania u pacjentów z chorobami przewlekłymi oraz wyższą skuteczność terapeutyczną od allopurynolu.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Ozierański, K., Rupiński , R., & Małecki , R. (2023). Febuksostat – skuteczna i bezpieczna alternatywa leczenia dny moczanowej. Punkty widzenia kardiologa, reumatologa i nefrologa . Medycyna Faktów , 16(4(61), 398-402. https://doi.org/10.24292/01.MF.0423.17
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Adenuric 80 mg – charakterystyka produktu leczniczego.
2. Becker MA, Schumacher HR Jr, Wortmann RL et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353(23): 2450-61.
3. Schumacher HR Jr, Becker MA, Wortmann RL et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008; 59(11): 1540-8.
4. Becker MA, Schumacher HR, Espinoza LR et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12(2): R63.
5. Mackenzie IS, Ford I, Nuki G et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020; 396(10264): 1745-57.
6. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012; 125(7): 679-87.e1.
7. FitzGerald JD, Dalbeth N, Mikuls T et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020; 72(6): 744-60.
8. Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76(1): 29-42.
9. Becker MA, Schumacher HR, MacDonald PA et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009; 36(6): 1273-82.
10. Schumacher HR Jr, Becker MA, Lloyd E et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009; 48(2): 188-94.
11. Agca R, Heslinga SC, Rollefstad S et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017; 76(1): 17-28.
12. Collison J. Crystal arthritis: Febuxostat reduces synovitis in early gout. Nat Rev Rheumatol. 2017; 13(12): 694.
13. Kraev KI, Geneva-Popova MG, Hristov BK et al. Celebrating Versatility: Febuxostat’s Multifaceted Therapeutic Application. Life (Basel). 2023; 13(11): 2199.
14. Stompór T, Adamczak M, Kurnatowska I et al. Pharmacological Nephroprotection in Non-Diabetic Chronic Kidney Disease-Clinical Practice Position Statement of the Polish Society of Nephrology. J Clin Med. 2023; 12(16): 5184.
15. Markel A. Allopurinol-induced DRESS syndrome. Isr Med Assoc J. 2005; 7(10): 656-60.
16. Yokose C, Lu N, Xie H et al. Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general population-based cohort study. Cmaj. 2019; 191(39): E1070-E1077.
17. O’Dell JR, Brophy MT, Pillinger MH et al. Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management. NEJM Evid. 2022; 1(3): 10.1056/evidoa2100028.
18. Konishi M, Kojima S, Uchiyama K et al. Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease. Int J Cardiol. 2022; 349: 127-33.
19. Yang N, Cao B. Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study. J Clin Pharm Ther. 2022; 47(12): 2214-22.
20. Kojima S, Matsui K, Hiramitsu S et al. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. Eur Heart J. 2019; 40(22): 1778-86.
21. Lin TC, Hung LY, Chen YC et al. Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(29): e16311.
2. Becker MA, Schumacher HR Jr, Wortmann RL et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353(23): 2450-61.
3. Schumacher HR Jr, Becker MA, Wortmann RL et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008; 59(11): 1540-8.
4. Becker MA, Schumacher HR, Espinoza LR et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12(2): R63.
5. Mackenzie IS, Ford I, Nuki G et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020; 396(10264): 1745-57.
6. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012; 125(7): 679-87.e1.
7. FitzGerald JD, Dalbeth N, Mikuls T et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020; 72(6): 744-60.
8. Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76(1): 29-42.
9. Becker MA, Schumacher HR, MacDonald PA et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009; 36(6): 1273-82.
10. Schumacher HR Jr, Becker MA, Lloyd E et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009; 48(2): 188-94.
11. Agca R, Heslinga SC, Rollefstad S et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017; 76(1): 17-28.
12. Collison J. Crystal arthritis: Febuxostat reduces synovitis in early gout. Nat Rev Rheumatol. 2017; 13(12): 694.
13. Kraev KI, Geneva-Popova MG, Hristov BK et al. Celebrating Versatility: Febuxostat’s Multifaceted Therapeutic Application. Life (Basel). 2023; 13(11): 2199.
14. Stompór T, Adamczak M, Kurnatowska I et al. Pharmacological Nephroprotection in Non-Diabetic Chronic Kidney Disease-Clinical Practice Position Statement of the Polish Society of Nephrology. J Clin Med. 2023; 12(16): 5184.
15. Markel A. Allopurinol-induced DRESS syndrome. Isr Med Assoc J. 2005; 7(10): 656-60.
16. Yokose C, Lu N, Xie H et al. Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general population-based cohort study. Cmaj. 2019; 191(39): E1070-E1077.
17. O’Dell JR, Brophy MT, Pillinger MH et al. Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management. NEJM Evid. 2022; 1(3): 10.1056/evidoa2100028.
18. Konishi M, Kojima S, Uchiyama K et al. Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease. Int J Cardiol. 2022; 349: 127-33.
19. Yang N, Cao B. Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: A double-centre, randomized, controlled study. J Clin Pharm Ther. 2022; 47(12): 2214-22.
20. Kojima S, Matsui K, Hiramitsu S et al. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. Eur Heart J. 2019; 40(22): 1778-86.
21. Lin TC, Hung LY, Chen YC et al. Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(29): e16311.